← SynDRA
DACINOSTAT
SynDRA canonical compound SYN0004827 — structure-anchored drug synonym record
Clinical phase
Phase 1
Primary target(s)
HDAC1 | HDAC2 | HDAC3 | HDAC4 | HDAC5 | HDAC6 | HDAC7 | HDAC8 | HDAC9
Mechanism of action
HDAC inhibitor
All known targets
HDAC1
HDAC2
HDAC3
HDAC4
HDAC5
HDAC6
HDAC7
HDAC8
HDAC9
Mechanisms of action (all sources)
histone deacetylase inhibitor
HDAC1 INHIBITOR
Cross-references
PubChem CID:
6445533
ChEMBL:
CHEMBL356066
DrugBank:
DB17034
ChEBI:
94063
TTD: D0B3FV
Synonyms
Laq-824
LAQ824
NVP-LAQ824
LAQ-824
LAQ824 (Dacinostat)
UNII-V10P524501
(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
CHEMBL356066
V10P524501
(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
Dacinostat [INN]
(E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide
(2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide
NVP-LAQ 824
NVP-LAQ824, Dacinostat, LAQ824
LBH539
2-Propenamide, N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-
Dacinostat (NVP-LAQ824, LAQ824)
(2e)-n-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide
LAQ824 (NVP-LAQ824,Dacinostat)
(2E)-N-Hydroxy-3-(4-(((2-hydroxyethyl)(2-(1H-indol-3-yl)ethyl)amino)methyl)phenyl)propenamide
(2E)-N-Hydroxy-3-(4-({(2-hydroxyethyl)(2-(1H-indol-3-yl)ethyl)amino}methyl)phenyl)propenamide
2-Propenamide, N-hydroxy-3-(4-(((2-hydroxyethyl)(2-(1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-
DACINOSTAT [WHO-DD]
SCHEMBL95240
MLS006010418
MLS006011098
SCHEMBL181782
GTPL7497
LAQ824,NVP-LAQ824
BDBM19428
CHEBI:94063
DTXSID50870351
BCP01747
EX-A2226
ZINC1494627
MFCD09970778
s1095
AKOS015899788
Look up DACINOSTAT in the interactive SynDRA portal →